Suppr超能文献

人卵巢非病变组织以及良性和恶性肿瘤中的胞质溶胶与核雌激素和孕激素受体及17β-羟类固醇脱氢酶活性

Cytosol and nuclear estrogen and progestin receptors and 17 beta-hydroxysteroid dehydrogenase activity in non-diseased tissue and in benign and malignant tumors of the human ovary.

作者信息

Vierikko P, Kauppila A, Vihko R

出版信息

Int J Cancer. 1983 Oct 15;32(4):413-22. doi: 10.1002/ijc.2910320404.

Abstract

Significant but low concentrations (mean 8 fmol/mg cytosol protein) of cytosol estrogen receptors were found in 57% of non-diseased ovarian tissues, and higher concentrations (mean 211) of cytosol progestin receptors in all these tissues. An approximately similar distribution was found for the presence of nuclear female sex steroid receptors; the mean concentrations were 159 and 1149 sites/cell, for estrogen and progestin receptors, respectively. There were no major differences in these parameters between pre- and postmenopausal non-diseased ovaries. The activities of ovarian 17 beta-hydroxysteroid dehydrogenase (17-HSD) did not display correlations between circulating progesterone concentrations in pre- or postmenopausal women with non-diseased ovaries. The majority of benign epithelial tumors contained significant concentrations of cytosol estrogen receptors, and all showed cytosol progestin receptors. The concentration of estrogen receptors was identical to that seen in non-diseased ovaries (mean 9 fmol/mg cytosol protein), whereas that of progestin receptor was significantly lower (mean 95). Nuclear female sex steroid receptors were measured in all benign tumors, and their concentrations were significantly higher than in normal ovaries (440 and 3218 sites/cell for estrogen and progestin receptors, respectively). No difference in 17-HSD activities were detected between normal ovaries and benign tumors. In malignant ovarian tumors, the picture was different from that found in normal ovarian tissues and benign tumors. Cytosol estrogen receptor was found in 89% of malignant epithelial tumors, and its concentration was significantly higher (mean 64 fmol/mg cytosol protein). Cytosol progestin receptor was found in 91%, and its concentration (mean 75) was significantly lower than in normal ovarian tissue or benign ovarian tumors. Nuclear female sex steroid receptor concentrations were intermediate between those seen in non-diseased ovaries an in benign tumors. 17-HSD activity was significantly lower than in other tissue categories studied. In the small group (16) of non-epithelial ovarian carcinomas cytosol estrogen receptors were not found, whereas the results of other measurements did not display any coherent picture. Breast and endometrial carcinoma metastatic to the ovary showed receptor patterns which were typical of the primary tumors. When the different clinical stages (I-IV) of malignant epithelial ovarian tumors were compared, 17-HSD activity was significantly higher in the least advanced clinical stage (I), whereas no significant differences were found in the other parameters measured.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

在57%的非病变卵巢组织中发现了浓度显著但较低(平均8飞摩尔/毫克胞浆蛋白)的胞浆雌激素受体,并且在所有这些组织中发现了浓度较高(平均211)的胞浆孕激素受体。核内雌性甾体激素受体的存在情况也呈现出大致相似的分布;雌激素和孕激素受体的平均浓度分别为159和1149个位点/细胞。绝经前和绝经后非病变卵巢在这些参数上没有重大差异。非病变卵巢的绝经前或绝经后女性中,卵巢17β-羟类固醇脱氢酶(17-HSD)的活性与循环孕酮浓度之间没有相关性。大多数良性上皮性肿瘤含有显著浓度的胞浆雌激素受体,并且都显示有胞浆孕激素受体。雌激素受体的浓度与非病变卵巢中的浓度相同(平均9飞摩尔/毫克胞浆蛋白),而孕激素受体的浓度则显著较低(平均95)。在所有良性肿瘤中都检测了核内雌性甾体激素受体,其浓度显著高于正常卵巢(雌激素和孕激素受体分别为440和3218个位点/细胞)。在正常卵巢和良性肿瘤之间未检测到17-HSD活性的差异。在恶性卵巢肿瘤中,情况与正常卵巢组织和良性肿瘤不同。在89%的恶性上皮性肿瘤中发现了胞浆雌激素受体,其浓度显著更高(平均64飞摩尔/毫克胞浆蛋白)。在91%的肿瘤中发现了胞浆孕激素受体,其浓度(平均75)显著低于正常卵巢组织或良性卵巢肿瘤。核内雌性甾体激素受体浓度介于非病变卵巢和良性肿瘤之间。17-HSD活性显著低于所研究的其他组织类型。在一小群(16例)非上皮性卵巢癌中未发现胞浆雌激素受体,而其他测量结果没有呈现出任何一致的情况。转移至卵巢的乳腺癌和子宫内膜癌显示出原发性肿瘤典型的受体模式。当比较恶性上皮性卵巢肿瘤的不同临床分期(I-IV期)时,17-HSD活性在最早期临床分期(I期)显著更高,而在所测量的其他参数中未发现显著差异。(摘要截选至400字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验